桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司 第七届董事会薪酬与考核委员会关于2022年限制性股票激励计划 相关事项的核查意见 桂林莱茵生物科技股份有限公司（以下简称"公司"）第七届董事会薪酬与考 核委员会根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 股权激励管理办法》（以下简称"《管理办法》"）和《深圳证券交易所股票上 市规则》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》等有关 法律、法规、规范性文件及《公司章程》的规定，对公司 2022 年限制性股票激 励计划（以下简称"本激励计划"、《激励计划》）首次授予部分第三个解除限 售期解除限售条件成就的相关事项进行核查，现发表如下意见： 一、关于本激励计划首次授予部分第三个解除限售期可解除限售激励对象 名单的核查意见 （一）公司符合《管理办法》第七条规定的实施股权激励的条件，公司具备 实施股权激励计划的主体资格，未发生《激励计划》规定不得解除限售的情形。 （二）公司本次激励计划首次授予部分第三个解除限售期可解除限售的激励 对象不存在《管理办法》第八条规定的不得成为激励对象的下列情形： 1、最近 12 个月内被证券交 ...

北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2022 年限制性股票激励计划首次授予部分 第三个解除限售期解除限售条件成就的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2022 年限制性股票激励计划首次授予部分 第三个解除限售期解除限售条件成就的法律意见 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2022 年限制性股票激励计划首次授予部分 第三个解除限售期解除限售条件成就的 法律意见 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2022 年限制性股票激励计划首次授予部分 第三个解除限售期解除限售条件成就的法律意见 行了充分的核查验证，保证本《法律意见》所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担 相应法律责任。 2．本所律师同意将本《法律意见》作为本次解除限售事宜所必备的法定文件之 一随其他材料一同公开披露，并就本所律师出具的《法律意见》内容的真实性、准 确 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次股东会无否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002166 证券简称：莱茵生物 公告编号：2025-067 桂林莱茵生物科技股份有限公司 2025年第二次临时股东会决议公告 一、会议的召开情况 1、会议届次：2025年第二次临时股东会 2、会议召集人：董事会 3、会议召开方式：现场表决与网络投票相结合，股东应选择现场投票、网络投票中的一种方式，如果 同一表决权出现重复投票表决的，以第一次投票表决结果为准。 4、会议时间及地点： 现场会议的召开时间为2025年11月13日下午15:00，现场会议的召开地点为桂林市临桂区人民南路19号 公司四楼会议室。 网络投票：通过深圳证券交易所交易系统投票的时间为2025年11月13日上午9:15一9:25，9:30一11:30以 及下午13:00一15:00；通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票时间为2025 年11 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-067 桂林莱茵生物科技股份有限公司 2025年第二次临时股东会决议公告 1、本次股东会无否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议的召开情况 1、会议届次：2025年第二次临时股东会 2、会议召集人：董事会 3、会议召开方式：现场表决与网络投票相结合，股东应选择现场投票、网 络投票中的一种方式，如果同一表决权出现重复投票表决的，以第一次投票表决 结果为准。 4、会议时间及地点： 现场会议的召开时间为2025年11月13日下午15:00，现场会议的召开地点为 桂林市临桂区人民南路19号公司四楼会议室。 网络投票：通过深圳证券交易所交易系统投票的时间为2025年11月13日上午 9:15—9:25，9:30—11:30以及下午13:00—15:00；通过深圳证券交易所互联网投票 系统（http://wltp.cninfo.com.cn）投票时间为2025年11月13日上午9:1 ...

2025 年第二次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 2025 年第二次临时股东会的法律意见 北京德恒律师事务所 北京德恒律师事务所 关于桂林莱茵生物科技股份有限公司 关于桂林莱茵生物科技股份有限公司 2025 年第二次临时股东会的 法律意见 德恒 01G20240916 号 致：桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司（以下简称"公司"）2025 年第二次临时 股东会（以下简称"本次会议"）于 2025 年 11 月 13 日（星期四）召开。北京 德恒律师事务所接受公司委托，指派李哲律师、王冰律师（以下简称"德恒律师"） 出席本次会议。根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）、《桂林莱茵生物科技股份有限公司章程》 （以下简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开程序、 现 ...

Group 1 - The core viewpoint of the article highlights that Rhine Biotech's overseas business revenue accounted for 61.23% in the first half of the year, with the United States being a significant market [1] - The reduction of tariffs on Chinese goods by the U.S. is expected to lower the company's export product costs, enhancing price competitiveness in the U.S. market and increasing profit elasticity [1] - The company will continue to closely monitor changes in tariff policies [1]

Core Viewpoint - The company, Rhein Biotech, faced a production safety accident on August 21, 2025, resulting in a fine of 600,000 yuan and recommendations for accountability for several management personnel [2][4]. Incident Details - The accident was caused by an operator's failure to follow safety protocols, leading to a flash explosion that resulted in one death and multiple injuries [3][4]. - The estimated property damage from the incident is over 2 million yuan [3]. Company Response - Rhein Biotech is accelerating the update and reconstruction of the affected drying workshop, with plans to resume operations by early 2026 [2]. - The company has engaged external experts to assess safety risks and has developed a detailed rectification plan, which will be supervised by government authorities [2][5]. Financial Performance - For the first three quarters of 2025, Rhein Biotech reported a revenue of 1.272 billion yuan, an increase of 8.73% year-on-year, but a net profit decline of 30.73% to 70.395 million yuan [6]. - The third quarter saw a revenue of 435 million yuan, down 2.09% year-on-year, with a net profit of 32.285 million yuan, a decrease of 12.10% [6]. Future Outlook - The company anticipates an improvement in gross margin in the fourth quarter due to seasonal production and sales increases, as well as the nearing full operation of new extraction facilities [6][7]. - Rhein Biotech's cash flow from operating activities reached 346 million yuan, a significant increase of 142.73% year-on-year, attributed to reduced raw material payments and increased sales collections [7]. - The company is focusing on customized services and product combinations to drive growth in its core natural sweetener business, with new product certifications expected to enhance production capacity [7].

Core Viewpoint - The company, Rhein Biotech, faced a production safety accident on August 21, 2025, resulting in a fine of 600,000 yuan and recommendations for accountability for several management personnel [1][2][3]. Incident Details - The accident was caused by an operator's failure to follow operational procedures, leading to a flash explosion that resulted in one death and multiple injuries [2][3]. - The estimated property damage from the incident is over 2 million yuan [2]. Company Response - The company is accelerating the update and reconstruction of the affected drying workshop, with plans to resume operations by early 2026 [1]. - External experts have been invited to assess safety risks and develop corrective measures, which will be supervised by government authorities [1][4]. Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.272 billion yuan, an increase of 8.73% year-on-year, but a net profit of 70.4 million yuan, a decrease of 30.73% [4][5]. - The third quarter saw a revenue decline of 2.09% and a net profit decrease of 12.10% compared to the previous year [5]. - The company attributes the decline in profit margins to tariffs and depreciation of new production capacity, but expects improvement in the fourth quarter due to seasonal demand and operational efficiency [5][6]. Cash Flow and Business Development - The net cash flow from operating activities for the first three quarters reached 346 million yuan, a significant increase of 142.73% year-on-year [6]. - The company is focusing on customized services and product combinations to drive growth in its core natural sweetener business, with recent FDA GRAS certification for a new product [6].

Core Viewpoint - The investigation into the "8·21" safety incident at Rhine Biotech revealed that the accident was caused by employee misconduct during operations, leading to a flash explosion due to improper equipment handling [1][2]. Group 1: Incident Details - The direct cause of the incident was identified as the operator failing to follow operational procedures, specifically not opening the vacuum pump valve and not securing all head clamps before starting the vacuum pump and hot water pump [1]. - The failure to create a negative pressure environment in the drying machine led to the expansion of steam and ethanol vapor, resulting in a high-pressure situation that caused the head to be ejected and ignited by static electricity, leading to a flash explosion [1]. Group 2: Regulatory Actions - The Guilin Emergency Management Bureau imposed a fine of 600,000 yuan on Rhine Biotech as a result of the incident [1]. - Recommendations were made for legal penalties against responsible personnel, including the workshop supervisor, team leader, EHS specialist, and production director, while the deceased operator was exempt from accountability [1]. Group 3: Company Response and Future Actions - In response to the incident, Rhine Biotech has implemented several corrective measures, including a comprehensive safety hazard inspection, hiring external experts for diagnostic evaluations, and enhancing safety training for all employees [2]. - The company has established a dual verification mechanism for key equipment and initiated special governance for safety production [2]. - The affected drying workshop area is undergoing accelerated reconstruction, expected to be operational by early 2026, while other drying workshops will ensure production continuity, indicating that the incident and penalties will not significantly impact normal operations [2].

Core Viewpoint - The direct cause of the "8·21" safety incident at Rhine Biotech (002166.SZ) was identified as the operator's failure to follow operational procedures, leading to a series of technical failures that resulted in an explosion [2] Group 1: Incident Details - The investigation revealed that the operator did not open the vacuum pump valve or secure all the head clamps after loading the 2 vacuum belt dryer, which prevented the equipment from creating a negative pressure environment [2] - During the heating process, the evaporation of moisture and ethanol in the dryer caused pressure buildup, leading to the ejection of the head and subsequent ignition of ethanol vapor due to static electricity [2] Group 2: Regulatory Actions - The Guilin City Emergency Management Bureau imposed a fine of 600,000 yuan on Rhine Biotech as a result of the incident [2] - Recommendations were made for legal penalties against the workshop supervisor, team leader, EHS specialist, and production director, while the deceased operator was exempt from accountability [2] Group 3: Company Response - Following the incident, Rhine Biotech has implemented several corrective measures, including a comprehensive safety hazard inspection and hiring external experts for diagnostic evaluations [3] - The company has enhanced safety training for all employees, established a dual-review mechanism for key equipment, and initiated special safety production governance [3] - The affected drying workshop area is undergoing accelerated reconstruction, expected to be operational by early 2026, while other drying workshops will ensure production continuity [3]